» Articles » PMID: 28289436

Lifestyle Factors and the Metabolic Syndrome in Schizophrenia: a Cross-sectional Study

Overview
Publisher Biomed Central
Specialty Psychiatry
Date 2017 Mar 15
PMID 28289436
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiometabolic disease is more common in patients with schizophrenia than the general population.

Aim: The purpose of the study was to assess lifestyle factors, including diet and exercise, in patients with schizophrenia and estimate the prevalence of metabolic syndrome.

Methods: This is a cross-sectional study of a representative group of outpatients with schizophrenia in Salford, UK. An interview supplemented by questionnaires was used to assess diet, physical activity, and cigarette and alcohol use. Likert scales assessed subjects' views of diet and activity. A physical examination and relevant blood tests were conducted.

Results: Thirty-seven people were included in the study. 92% of men had central adiposity, as did 91.7% of women (International Diabetes Federation Definition). The mean age was 46.2 years and mean illness duration was 11.6 years. 67.6% fulfilled criteria for the metabolic syndrome. The mean number of fruit and vegetable portions per day was 2.8 ± 1.8. Over a third did not eat any fruit in a typical week. 42% reported doing no vigorous activity in a typical week. 64.9% smoked and in many cigarette use was heavy. The Likert scale showed that a high proportion of patients had insight into their unhealthy lifestyles.

Conclusions: Within this sample, there was a high prevalence of poor diet, smoking and inadequate exercise. Many did not follow national recommendations for dietary intake of fruit and vegetables and daily exercise. These factors probably contribute to the high prevalence of metabolic syndrome. Many had insight into their unhealthy lifestyles. Thus, there is potential for interventions to improve lifestyle factors and reduce the risk of cardiometabolic disease.

Citing Articles

Metabolic syndrome in patients with schizophrenia: Underlying mechanisms and therapeutic approaches (Review).

Manta A, Georganta A, Roumpou A, Zoumpourlis V, Spandidos D, Rizos E Mol Med Rep. 2025; 31(5).

PMID: 40017113 PMC: 11894597. DOI: 10.3892/mmr.2025.13479.


Transmural collaborative care model for cardiovascular risk management and medication review in patients using antipsychotics in primary care (TACTIC): A study protocol of an incomplete stepped wedge cluster randomized trial.

Jakobs K, van den Brule-Barnhoorn K, van Lieshout J, Janzing J, Cahn W, Kievit W Contemp Clin Trials Commun. 2025; 44:101418.

PMID: 39897941 PMC: 11787019. DOI: 10.1016/j.conctc.2024.101418.


Educational Nutrition Workshops: Impact on Nutritional Status in Organized Living Beneficiaries with Severe Mental Disorders and Their Caregivers.

Soher L, Cvijetic Stokanovic M, Prsa S, cacic Kenjeric D Nutrients. 2024; 16(22).

PMID: 39599708 PMC: 11597513. DOI: 10.3390/nu16223922.


Peripheral Lipid Signatures, Metabolic Dysfunction, and Pathophysiology in Schizophrenia Spectrum Disorders.

Wu S, Panganiban K, Lee J, Li D, Smith E, Maksyutynska K Metabolites. 2024; 14(9).

PMID: 39330482 PMC: 11434505. DOI: 10.3390/metabo14090475.


Influencing factors of different metabolic status in hospitalized patients with schizophrenia.

Ding M, Zhang S, Zhu Z, Cai R, Fang J, Zhou C Front Psychiatry. 2024; 15:1436142.

PMID: 39091455 PMC: 11291240. DOI: 10.3389/fpsyt.2024.1436142.


References
1.
Osborn D, Levy G, Nazareth I, Petersen I, Islam A, King M . Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. 2007; 64(2):242-9. DOI: 10.1001/archpsyc.64.2.242. View

2.
Bushe C, Haddad P, Peveler R, Pendlebury J . The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol. 2005; 19(6 Suppl):28-35. DOI: 10.1177/0269881105058682. View

3.
Holt R, Abdelrahman T, Hirsch M, Dhesi Z, George T, Blincoe T . The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness. J Psychopharmacol. 2009; 24(6):867-73. DOI: 10.1177/0269881109102788. View

4.
Haddad P, Sharma S . Adverse effects of atypical antipsychotics : differential risk and clinical implications. CNS Drugs. 2007; 21(11):911-36. DOI: 10.2165/00023210-200721110-00004. View

5.
Peet M . Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry Suppl. 2004; 47:S102-5. DOI: 10.1192/bjp.184.47.s102. View